Friday, ImmunityBio said the two complete responses are ongoing after seven and 15 months. The patients received four cycles ...

Durable complete responses with CAR-NK + Rituximab in patients who failed current standards of care in Waldenstrom’s ...

Artiva Biotherapeutics is developing NK cell immunotherapy for autoimmune disease. Early trial data in B-cell lymphoma ...

Cell-based immunotherapies have transformed cancer treatment, yet their widespread use remains constrained by safety risks, ...

Chimeric antigen receptor natural killer (CAR-NK) cell therapy is emerging as a promising next-generation immunotherapy with ...

Hangzhou Qihan Biotech Co., Ltd. (“Qihan” or “Qihan Biotech” or “the Company”), an industry leader in applying multiplexable genome editing technology to cell therapies and organ transplantation, ...

Phase 1/2 clinical study of NY-ESO-1 TCR/IL-15 NK for relapsed or refractory multiple myeloma commences on track NY-ESO-1 TCR/IL-15 NK is the lead clinical program of Syena, a Replay and MD Anderson ...

COEPTIS, Inc. has established GEAR Therapeutics as a majority-owned subsidiary to advance its GEAR-modified natural killer (NK) cell therapy into first-in-human studies targeting various cancers and ...

Natural killer cells, or NK cells, are elements of the immune system capable of rapidly locating and destroying cancerous or ...

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates ...